Study Stopped
Study closed due to change in personnel.
Dopamine and Motor Learning in Cerebral Palsy
2 other identifiers
observational
28
1 country
1
Brief Summary
Background: Cerebral palsy (CP) is the most common childhood motor disability. The neurotransmitter dopamine (DA) is important in cognition and emotions/behavior. DA may also be important in motor skill learning. Genes that relate to DA function may affect a person s ability to learn new cognitive or motor skills. Some children with CP can learn motor skills easily while others have trouble. Researchers want to find out if DA gene variations cause some of this variability. Objectives: To learn more about how DA and its related genes affect motor and cognitive learning in people with and without CP. Eligibility: People ages 5 25 with and without CP who can: Follow the protocol Attend and perform the training sessions Design: Participants will be screened with: Medical history Physical exam Blood draw for genetic tests The study has 2 parts. Participants with CP can join both. Those without can join only Part 1. All participants will have a baseline assessment: short motor skills test and blood draw. Part 1: Two 10-session training programs over 2 weeks. Cognitive training will be 2 sessions at the clinic, 8 at home. Participants will perform memory tasks on a computer. All 10 motor training sessions are at the clinic. Participants will step on lines in a virtual reality environment. Part 2: Two lab training sessions at least 1 week apart. Participants will perform tasks on a computer. Participants with CP may have a brain MRI at 1 visit. They will lie on a table that slides into a machine that takes pictures. They will be in the scanner about 45 minutes. They may have a
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 19, 2016
CompletedFirst Posted
Study publicly available on registry
July 21, 2016
CompletedStudy Start
First participant enrolled
June 21, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 10, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
November 12, 2024
CompletedNovember 19, 2024
November 1, 2024
4.5 years
July 19, 2016
November 15, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Learning (specific measures vary by task)
There will be two tasks : 1 a motor task which involves walking across a horizontal ladder. 2. Computer base tasks targeting working memory and procedural learning
measure of learning of each training task across the entire training period
Genetic testing (for dopamine and activity-related genes)
COMT, BDNF, DAT, and DRD1, DRD2, DRD3
genetic analyses of individual variations
Study Arms (2)
Cerebral Palsy
Children and young adults with Cerebral Palsy.
Healthy Volunteer
Children and young adults healthy volunteer
Eligibility Criteria
A maximum of 120 ambulatory children and young adults with and without CP (ages 5-25 inclusive) will be enrolled in this protocol.
You may qualify if:
- For all subjects:
- Ages 5-25 inclusive
- Able to follow the study protocol
- Able to attend or perform the training sessions as scheduled
- Additional criteria for subjects with CP:
- Diagnosis of cerebral palsy
- Gross Motor Functional Classification Scale Level I-II (able to walk at least 10 meters without an assistive device)
You may not qualify if:
- For all subjects:
- \. Presence of an injury or other medical condition (besides CP) that would affect motor function or the ability to perform the motor training program.
- Additional criteria for subjects with CP:
- Less than 6 months after major surgery to their legs
- Currently taking levodopa, trihexyphenidyl, methylphenidate or baclofen since these may affect dopamine transmission or neuroplasticity.
- Additional criteria for those with CP who choose to have an MRI:
- \. Have any of the following contraindications to having an MRI scan:
- Pregnancy
- A ventriculo-peritoneal shunt
- Have claustrophobia and not comfortable in small enclosed spaces
- Have metal that would make an MRI scan unsafe such as: cardiac pacemaker, insulin infusion pump, implanted drug infusion devise, cochlear or ear implant, transdermal medication patch (nitroglycerine), any metallic implants or objects, body piercing that cannot be removed, bone or joint pin, screw, nail, plate, wire sutures or surgical staples, shunts, cerebral aneurysms clips, shrapnel or other metal embedded (such as from war wounds or accidents or previous work in metal fields or machines that may have left any metallic fragments in or near your eyes).
- Excessive startle reaction to or fear of loud noises
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Related Publications (3)
Qian Y, Chen M, Forssberg H, Diaz Heijtz R. Genetic variation in dopamine-related gene expression influences motor skill learning in mice. Genes Brain Behav. 2013 Aug;12(6):604-14. doi: 10.1111/gbb.12062. Epub 2013 Jul 17.
PMID: 23819855BACKGROUNDPearson-Fuhrhop KM, Minton B, Acevedo D, Shahbaba B, Cramer SC. Genetic variation in the human brain dopamine system influences motor learning and its modulation by L-Dopa. PLoS One. 2013 Apr 17;8(4):e61197. doi: 10.1371/journal.pone.0061197. Print 2013.
PMID: 23613810BACKGROUNDMolina-Luna K, Pekanovic A, Rohrich S, Hertler B, Schubring-Giese M, Rioult-Pedotti MS, Luft AR. Dopamine in motor cortex is necessary for skill learning and synaptic plasticity. PLoS One. 2009 Sep 17;4(9):e7082. doi: 10.1371/journal.pone.0007082.
PMID: 19759902BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Diane L Damiano, Ph.D.
National Institutes of Health Clinical Center (CC)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NIH
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 19, 2016
First Posted
July 21, 2016
Study Start
June 21, 2017
Primary Completion
December 10, 2021
Study Completion
November 12, 2024
Last Updated
November 19, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will share
Only data without participants protected health information or identifiers will be shared.